The post Expert: 2 ASX healthcare stocks to avoid before reporting season appeared first on The Motley Fool Australia.

"And while the Cochlear Nucleus Nexa System introduces several enhancements, it is based on the existing Nucleus 8 platform, with improvements appearing incremental and more about refining the ...

It was a bumpy ride for ASX health stocks over the past week amid Trump's renewed threat to impose tariffs ... Read More The ...

Cochlear Ltd. heard good news from the U.S. FDA, as the agency approved its next-generation cochlear implant, the Nucleus Nexa System, the first smart cochlear implant system. Cochlear expects to ...

Cochlear Limited, the global leader in implantable hearing solutions, announced the US Food and Drug Administration (FDA) approval of the Cochlear Nucleus Nexa System – the world’s first and only, ...

An update from Cochlear ( (AU:COH) ) is now available.

Upgradeable Firmware: The Cochlear™ Nucleus® Nexa™ System features upgradeable firmware on the implant – an industry first, allowing recipients to access future innovation through firmware ...

LONE TREE, Colo., July 8, 2025 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S Food and Drug Administration (FDA) approval of ...

The Nucleus Nexa System builds upon Cochlear's industry-leading portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of ...